6-amino-2-methylheptan-2-ol,hydrochloride structure
|
Common Name | 6-amino-2-methylheptan-2-ol,hydrochloride | ||
---|---|---|---|---|
CAS Number | 543-15-7 | Molecular Weight | 181.70300 | |
Density | 0.895g/cm3 | Boiling Point | 250.1ºC at 760mmHg | |
Molecular Formula | C8H20ClNO | Melting Point | 165-167 °C(lit.) | |
MSDS | N/A | Flash Point | 105.1ºC |
Use of 6-amino-2-methylheptan-2-ol,hydrochlorideHeptaminol hydrochloride is a vasoconstrictor, used in the treatment of low blood pressure, particularly orthostatic hypotension.in vivo: In the rat, Heptaminol hydrochloride prevents orthostatic hypotension, and increases the noradrenaline plasma concentration. In bovine chromaffin cells maintained in primary cultures, Heptaminol hydrochloride is found to be a competitive inhibitor of noradrenaline uptake.[1] |
Name | 6-amino-2-methylheptan-2-ol,hydrochloride |
---|---|
Synonym | More Synonyms |
Description | Heptaminol hydrochloride is a vasoconstrictor, used in the treatment of low blood pressure, particularly orthostatic hypotension.in vivo: In the rat, Heptaminol hydrochloride prevents orthostatic hypotension, and increases the noradrenaline plasma concentration. In bovine chromaffin cells maintained in primary cultures, Heptaminol hydrochloride is found to be a competitive inhibitor of noradrenaline uptake.[1] |
---|---|
Related Catalog | |
References |
[1]. Pourrias B, et al. Heptaminol chlorhydrate: new data. Ann Pharm Fr. 1991;49(3):127-138. |
Density | 0.895g/cm3 |
---|---|
Boiling Point | 250.1ºC at 760mmHg |
Melting Point | 165-167 °C(lit.) |
Molecular Formula | C8H20ClNO |
Molecular Weight | 181.70300 |
Flash Point | 105.1ºC |
Exact Mass | 181.12300 |
PSA | 46.25000 |
LogP | 2.77710 |
Storage condition | 2-8℃ |
Synonym:Heptaminol Hydrochloride; Heptaminyl Hydrochloride; 2-Heptylamine Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
Risk Phrases: 22 Section 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW
Harmful if swallowed.The toxicological properties of this material have not been fully investigated.Hygroscopic (absorbs moisture from the air). Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. Ingestion: The toxicological properties of this substance have not been fully investigated. Inhalation: May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Chronic: No information found. Section 4 - FIRST AID MEASURES Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid. Skin: Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse. Ingestion: Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water. Get medical aid. Wash mouth out with water. Inhalation: Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Notes to Physician: Section 5 - FIRE FIGHTING MEASURES General Information: As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Extinguishing Media: Use water spray, dry chemical, carbon dioxide, or chemical foam. Section 6 - ACCIDENTAL RELEASE MEASURES General Information: Use proper personal protective equipment as indicated in Section 8. Spills/Leaks: Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation. Section 7 - HANDLING and STORAGE Handling: Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with skin and eyes. Avoid ingestion and inhalation. Storage: Store in a cool, dry place. Store in a tightly closed container. Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION Engineering Controls: Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 543-15-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin: Wear appropriate protective gloves to prevent skin exposure. Clothing: Wear appropriate protective clothing to prevent skin exposure. Respirators: Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced. Section 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical State: Solid Color: white to off-white Odor: odorless pH: Not available. Vapor Pressure: Not available. Viscosity: Not available. Boiling Point: Not available. Freezing/Melting Point: 160 - 165 deg C Autoignition Temperature: Not applicable. Flash Point: Not applicable. Explosion Limits, lower: Not available. Explosion Limits, upper: Not available. Decomposition Temperature: Solubility in water: soluble Specific Gravity/Density: Molecular Formula: C8H19NO.HCl Molecular Weight: 145.1391 Section 10 - STABILITY AND REACTIVITY Chemical Stability: Stable under normal temperatures and pressures. Conditions to Avoid: Incompatible materials, dust generation, exposure to moist air or water. Incompatibilities with Other Materials: Strong oxidizing agents, strong bases. Hazardous Decomposition Products: Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide. Hazardous Polymerization: Has not been reported Section 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 543-15-7: MJ3240000 LD50/LC50: Not available. Carcinogenicity: 6-Amino-2-methyl-2-heptanol hydrochloride - Not listed by ACGIH, IARC, or NTP. Other: See actual entry in RTECS for complete information. Section 12 - ECOLOGICAL INFORMATION Section 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations. Section 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material. Section 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives Hazard Symbols: XN Risk Phrases: R 22 Harmful if swallowed. Safety Phrases: WGK (Water Danger/Protection) CAS# 543-15-7: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 543-15-7 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 543-15-7 is not listed on the TSCA inventory. It is for research and development use only. SECTION 16 - ADDITIONAL INFORMATION N/A |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Hazard Codes | Xi |
---|---|
Risk Phrases | 36/37/38 |
Safety Phrases | S22-S24/25 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | MJ3240000 |
HS Code | 2922199090 |
HS Code | 2922199090 |
---|---|
Summary | 2922199090. other amino-alcohols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Metabolism of isometheptene in human urine and analysis by gas chromatography-mass spectrometry in doping control.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 827(2) , 199-204, (2005) A study of the metabolism of isometheptene, an antispasmodic drug, in man and comparison with heptaminol metabolism, is presented in this paper. Isometheptene and two metabolites were detected in huma... |
|
Double-blind plethysmographic study of venous effects of heptaminol adenosine phosphate in patients with primary varicose veins.
Eur. J. Clin. Pharmacol. 37(1) , 37-40, (1989) Changes in venous haemodynamics were studied after administration of a single dose of 3 g Heptaminol Adenosine Phosphate (HAP) to 30 subjects with primary varicose veins. Strain gauge plethysmography ... |
|
Measurement of lymphatic flow variation by noninvasive method cases of lymphedema.
Angiology 43(7) , 567-71, (1992) The purpose of this study was to measure the variations of lymphatic flow. A noninvasive isotopic method was used to achieve a functional exploration of lymphatic circulation. Fifteen subjects were us... |
6-hydroxy-6-methyl-2-heptylamine hydrochloride |
Heptylon tropfen |
6-amino-2-methyl-2-heptanol hydrochloride |
Heptamyl tropfen |
Coreptil |
MFCD00013015 |
6-Amino-2-methyl-heptan-2-ol,Hydrochlorid |
Delmiton |
Arcor tropfen |
Cardiosintol |
Heptaminol HCl |
Cortensor |
EINECS 208-837-5 |
6-amino-2-methyl-heptan-2-ol,hydrochloride |
heptaminol hydrochloride |